Efficacy and safety of clomipramine for post COVID-19 condition: exploratory research

oda Takamasa0 个研究点目标入组 20 人开始时间: 2023年11月21日最近更新: 2024年1月22日

适应症

试验速览

暂无简介。

•Patients who meet all of the following selection criteria and who have obtained sufficient understanding and written consent from the research subject about the contents of this research are eligible for this research.
•1) Participants must be meet the WHO-defined Long COVID
•2) On the C19-YRSm First Assessment (overall health score) on > 2 points more severe than their pre-COVID baseline
•3) 18 to 59 years old
•4) Participants attending the outpatient clinic of the research facility
•5) Participants are competent to consent and consent is obtained in writing

•Any potential subject who meets the following criteria will be excluded from participating in the study.
•1) Participant has a history of substance abuse (drug or alchol) or dependence.
•2) Participant has contraindications to taking clomipramine
•3) There is a change in a regular prescription drug during the period from 2 weeks before the study participation period to the end
•4) Pregnant or lactating
•5) Not a native Japanese speaker
•6) Participant considered by the principal investigator and sub-investigator(s) to be inappropriate for the safe conduct of the study.

发起方

oda Takamasa